JCPyV-specific virus-specific T-cell therapy (adoptive cellular immunotherapy) consisting of HLA-restricted T cells infused IV (1×10^8 cells every 28 days for 4 doses) to restore antiviral cytotoxic T-lymphocyte responses (primarily CD8+) against JCPyV-infected CNS cells, control viral replication, and slow/stop PML progression.
Adoptive transfer of ex vivo expanded, HLA-restricted JCPyV-specific T cells (primarily CD8+ cytotoxic T lymphocytes) that recognize JCPyV antigens via native TCRs on infected CNS cells and eliminate them via cytotoxic effector functions and Th1 cytokines, restoring antiviral cellular immunity to control viral replication and slow or halt PML progression.
HLA-restricted recognition of JCPyV VP2–derived peptides on MHC I by infused JCPyV-specific CD8+ T cells triggers cytotoxic killing via perforin/granzyme and Fas–FasL pathways.
JCPyV-specific virus-specific T-cell therapy (adoptive cellular immunotherapy) consisting of HLA-restricted T cells infused IV (1×10^8 cells every 28 days for 4 doses) to restore antiviral cytotoxic T-lymphocyte responses (primarily CD8+) against JCPyV-infected CNS cells, control viral replication, and slow/stop PML progression.
Adoptive transfer of ex vivo expanded, HLA-restricted JCPyV-specific T cells (primarily CD8+ cytotoxic T lymphocytes) that recognize JCPyV antigens via native TCRs on infected CNS cells and eliminate them via cytotoxic effector functions and Th1 cytokines, restoring antiviral cellular immunity to control viral replication and slow or halt PML progression.
Adoptively transferred JCPyV-specific CD8+ T cells recognize VP3-derived peptides presented on HLA class I and directly kill infected cells via perforin/granzyme-mediated cytolysis (and Fas–FasL pathways).
JCPyV-specific virus-specific T-cell therapy (adoptive cellular immunotherapy) consisting of HLA-restricted T cells infused IV (1×10^8 cells every 28 days for 4 doses) to restore antiviral cytotoxic T-lymphocyte responses (primarily CD8+) against JCPyV-infected CNS cells, control viral replication, and slow/stop PML progression.
Adoptive transfer of ex vivo expanded, HLA-restricted JCPyV-specific T cells (primarily CD8+ cytotoxic T lymphocytes) that recognize JCPyV antigens via native TCRs on infected CNS cells and eliminate them via cytotoxic effector functions and Th1 cytokines, restoring antiviral cellular immunity to control viral replication and slow or halt PML progression.
Adoptively transferred HLA-restricted JCPyV-specific CD8+ T cells recognize JCPyV agnoprotein peptides on MHC I and kill infected cells via perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis).
T-cell-engaging bispecific monoclonal antibody that binds bivalently to CD20 on B cells and monovalently to CD3 on T cells to redirect T-cell cytotoxicity.
CD20xCD3 bispecific antibody that binds bivalently to CD20 on B cells and monovalently to CD3 on T cells, bridging T cells to malignant B cells to activate T-cell cytotoxicity and kill CD20-positive tumor cells.
Bispecific CD20xCD3 antibody bridges T cells to CD20+ cells, activating T-cell cytotoxicity (perforin/granzyme and Fas–FasL) to kill the target-expressing cells.